| 08.20 | Welcome speech Pier Mannuccio Mannucci, Flora Peyvandi, Augusto B Federici, Nicola Ciavarella |
| SCIENTIFIC SESSION 1 – Hemophilia Chairs: Nicola Ciavarella, David Lillicrap |
|
| 08.30 | Will severe hemophilia become more common in the future? The effects of population demographics on the prevalence of hemophilia Manuel Carcao, Canada |
| 09.00 | Determinants of factor VIII inhibitor risk. Is von Willebrand factor a key factor? David Lillicrap, Canada |
| 09.30 | Endocytosis of factor VIII by antigen-presenting cells: roles of von Willebrand factor and complement Sebastien Lacroix-Desmazes, France |
| 10.00 | Paradigm shift of the treatment of hemophilia A by factor VIII mimicking bispecific antibody Midori Shima, Japan |
| 10.30 | The challenges of innovative therapeutic interventions in hemophilia Louis M. Aledort, USA |
| 11.00 | Break & Poster Session VIEW PAGE |
| SCIENTIFIC SESSION 2 – Von Willebrand disease Chairs: Giancarlo Castaman, Augusto B. Federici |
|
| 11.30 | Von Willebrand factor regulation of blood vessel formation and function Anna Maria Randi, UK |
| 12.00 | Gastrointestinal bleeding in von Willebrand disease: an unresolved problem Giancarlo Castaman, Italy |
| 12.30 | The potential use of nanobodies In the treatment of von Willebrand disease (VWD) and hemophilia Peter Lenting, France |
| 13.00 | Lunch & Poster Session VIEW PAGE |
| ORAL COMMUNICATIONS Chairs: Pier Mannuccio Mannucci, Massimo Franchini |
|
| 14.30 | Desmopressin (DDVAP): 40 years after Pharmacokinetic modelling to predict FVIII:C response to desmopressin and its reproducibility in non-severe hemophilia A patients Lisette Schütte (the Netherlands) Perioperative management of von Willebrand patients with desmopressin: Towards a predictive population PK model Jessica Heijdra (the Netherlands) The effect of F8 missense mutations on individual pharmacokinetic parameters of DDAVP response in nonsevere hemophilia A Janneke Loomans (the Netherlands) The intracellular binding of FVIII to VWF may allow a clinically useful response to DDAVP in patients with hemophilia A due to FVIII mutations impairing FVIII binding to VWF Marc Jacquemin (Belgium) Desmopressin in moderate hemophilia A patients: a treatment worth considering Janneke Loomans (the Netherlands) Safety and effectiveness of desmopressin for the management of bleeds, delivery and major surgery in mild-moderate von Willebrand disease: Results of the Pro-Des-Wil study in a cohort of 84 patients Augusto Federici (Italy) |
| SATELLITE LECTURE/SYMPOSIA | |
| 15.30 | Satellite Symposium Sponsored by Sobi Beyond half-life extension: characterising how rFVIIIFc impacts the immune system VIEW PAGE |
| 16.30 | Break & Poster Session VIEW PAGE |
| SCIENTIFIC SESSION 3 – Thrombotic microangiopathies Chairs: Flora Peyvandi, Johana Kremer Hovinga |
|
| 17.00 | Mechanism of thrombotic microangiopathy: lesson from zebrafish to men X. Long Zheng, USA |
| 17.30 | Differential diagnosis of thrombotic microangiopathies Jeffrey C. Laurence, USA |
| 18.00 | Immune repertoire in acquired TTP Johana Kramer Hovinga, Switzerland |
SCHEDULE
